Earlier scientific literatures stated that the activity of cytochrome P450 enzymes in the GIT wall is the utmost significant aspects which can change the bioavailability of orally consumed anti-cancer drugs that are substrates of CYP3A [95]. The gene discussed is CYP3A4; the disease is cancer.